Phaseline

Targets › MYC

MYC (Myc proto-oncogene protein): drug programs, companies and trials

6 programs from 6 companies in 8 trials: 4 Phase 1, 3 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.

Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. (UniProt, P01106)

Open in Phaseline: the race on MYC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
European Organisation for Research and Treatment of Cancer - EORTCABVD regimen
Combination of doxorubicin, bleomycin, vinblastine, and dacarbazine - multi-modal chemothe
Tubulin, TOP2A, MYCPhase 3Lymphoma–
Institute of Hematology & Blood Diseases Hospital, ChinaDVRd
Daratumumab (CD38 monoclonal antibody), Velcade (proteasome inhibitor), and dexamethasone
PSMD1, TP53, MYCPhase 2Multiple MyelomaDec 2026
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsZEN-3694
MYC inhibitor
MYCPhase 2Metastatic Castration-resistant Prostate CancerAug 2031
IDP Discovery PharmaIDP-121
cMyc protein antagonist
MYCPhase 1Multiple Myeloma (MM); Small Cell Lung Cancer ( SCLC )Jul 2028
National Institute of Neurological Disorders and Stroke (NINDS)LMP744
Indenoisoquinolone C-MYC/TOPOISOMERASE 1 inhibitor
MYC, TOP1Phase 1Recurrent GlioblastomaDec 2030
PeptomycOMO-103
Myc inhibitor
MYCPhase 1Metastatic Pancreatic Cancer; Osteosarcoma–

Conditions

Recurrent Glioblastoma (1) Lymphoma (1) Multiple Myeloma (1) Metastatic Pancreatic Cancer (1) Osteosarcoma (1) Metastatic Castration-resistant Prostate Cancer (1) Multiple Myeloma (MM) (1) Small Cell Lung Cancer ( SCLC ) (1)

Modalities

small molecule (5), mixed (1)

Companies

National Institute of Neurological Disorders and Stroke (NINDS) (1) European Organisation for Research and Treatment of Cancer - EORTC (1) Institute of Hematology & Blood Diseases Hospital, China (1) Peptomyc (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) IDP Discovery Pharma (1)

Related targets

TOP1 (1) Tubulin (1) TOP2A (1) PSMD1 (1) TP53 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.